Viva Biotech Holdings (1873) AI Stock Analysis

• Market Cap: HK$4.21B
• Dividend Yield: N/A
• Average Volume (3M): 10.31M
• Price to Earnings (P/E): 7.0
• Beta (1Y): 2.34
• Revenue Growth: -8.11%
• EPS Growth: N/A
• Country: HK
• Employees: 2,063
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,129,882,300
• 10 Day Avg. Volume: 10,852,121
• 30 Day Avg. Volume: 10,305,290
• PEG Ratio: -0.04
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 0.87
• P/FCF Ratio: 9.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 0.12
• Revenue Forecast (FY): HK$2.17B

• Rating: 55 Neutral
• Price Target: HK$2.50 ▲(42.05% Upside)
• Action: Upgraded Date: 01/27/26
• Date: Action: Upgraded 01/27/26

The score is held back primarily by uneven financial performance—especially operating cash flow dropping to zero and revenue volatility—despite a relatively solid balance sheet and improving profitability in 2024. Technicals are supportive (price above key moving averages and positive MACD) but are tempered by overbought signals (RSI/Stoch). Valuation is also a constraint with a high P/E and no dividend yield data.

Positive Factors

Service-based business model

Viva's core drug discovery and development services, plus partnerships that produce milestone payments and licensing, create diversified revenue channels. This business model is durable: outsourced R&D demand and milestone economics support recurring project work and upsides from successful programs.

Negative Factors

Operating cash flow instability

A drop to zero operating cash flow signals weak cash generation from core activities and undermines self-funding ability for R&D and working capital. If this pattern persists, the firm may require external financing, increasing dilution or leverage and constraining strategic flexibility over coming quarters.

Viva Biotech Holdings Business Overview & Revenue Model

Company Description

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purific...

Read more

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purific...

How the Company Makes Money

Viva Biotech generates revenue through multiple key streams primarily centered around its drug discovery and development services. The company charges clients for its specialized services, which include high-throughput screening, lead optimization...

Read more

Viva Biotech generates revenue through multiple key streams primarily centered around its drug discovery and development services. The company charges clients for its specialized services, which include high-throughput screening, lead optimization...

Viva Biotech Holdings Financial Statement Overview

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.84B	1.99B	2.16B	2.38B	2.10B	696.96M
Gross Profit	687.68M	687.40M	738.43M	815.68M	650.98M	304.87M
EBITDA	427.18M	428.00M	391.01M	436.35M	369.94M	164.35M
Net Income	172.29M	167.29M	-116.11M	-528.48M	287.55M	-386.88M
Balance Sheet
Total Assets	6.88B	7.05B	7.45B	7.92B	8.04B	8.15B
Cash, Cash Equivalents and Short-Term Investments	904.45M	941.58M	1.04B	678.57M	800.95M	2.36B
Total Debt	1.16B	1.28B	1.90B	2.82B	2.65B	2.97B
Total Liabilities	2.98B	3.23B	3.76B	4.32B	4.13B	4.40B
Stockholders Equity	3.89B	3.80B	3.69B	3.60B	3.91B	3.76B
Cash Flow
Free Cash Flow	214.34M	182.32M	195.57M	136.72M	-487.35M	-549.44M
Operating Cash Flow	351.48M	373.99M	383.40M	386.05M	77.83M	43.18M
Investing Cash Flow	-29.84M	185.90M	439.17M	-372.80M	-868.84M	-3.85B
Financing Cash Flow	-455.14M	-657.76M	-429.50M	-143.20M	-653.16M	5.31B

Viva Biotech Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1873, the sentiment is Neutral. The current price of 1.76 is below the 20-day moving average (MA) of 2.12, below the 50-day MA of 2.23, and below the 200-day MA of 2.13, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 48.39 is Neutral, neither overbought nor oversold. The STOCH value of 31.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1873.

Viva Biotech Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2696	66 Neutral	HK$25.21B	34.57	25.67%	―	2.57%	18.79%
1873	55 Neutral	HK$4.21B	7.02	4.48%	―	-8.11%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1877	45 Neutral	HK$35.64B	-18.01	-14.53%	―	38.56%	48.26%
2157	40 Underperform	HK$10.06B	30.77	24.17%	―	240.05%	-140.09%

Viva Biotech Holdings Corporate Events